Comparison of Efficacy and Side Effect Between Albendazole, Albendazole-Levamisole and Mebendazole-Levamisole Againts Soil-Transmitted Helminths Infection at a Public Elementary School-Age Children on The Deli Serdang Regency
DOI:
https://doi.org/10.35814/jifi.v15i2.511Keywords:
Soil Transmitted Helminths, Albendazol, Albendazol-Levamisol, Mebendazol-LevamisolAbstract
Intestinal worm infection in particular of Soil Transmitted Helminth is still a global problem with high prevalence on the tropic and subtropic regions including Indonesia especially in the rural community. Double Blind Randomized Trial that started from April to June 2015 in which the samples are collected from public elementary school children on the Deli Serdang Regency to compare the effectivity and side effect of STH infection treatment by using Albendazole 400 mg, Albendazole 400 mg-Levamisol 50 mg/100 mg, Mebendazole 500 mg-Levamisol 50 mg/100 mg. The samples of Albendazole, Albendazole-Levamisol and Mebendazole-Levamisol groups consist of 60 children in each group in which the ones that have STH infection are Ascariasis 92 children 51.11%, Trichuriasis 37 children 20.55%, and mixed infection 51 children 28.33%. In this research, researcher doesn’t found hookworm infection in any of the groups. From the result of
stool examination, researcher found 100% of cure rate for A. lumbricoides infection on all groups, cure rate of T. trichiura infection 66.7%, 94.7%, 92.3% for each Albendazole, Albendazole-Levamisol, and Mebendazole-Levamisol groups meanwhile cure rate for mixed infection are 28.6%, 85.7%, and 66.7% for each Albendazole, Albendazole-Levamisoland Mebendazole- Levamisol groups. For mild T.trichiura infection treatment with singledose of Albendazole-Levamisol
group is better than both of Albendazole and Mebendazole- Levamisole groups (p=0.01). In this research, researcher found nausea and diarrhea as treatment of side effect and no signifi cant difference of side effect in all groups of treatment.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















